Leela Barham Archives -

What can Linux and Mozilla teach ICER about how to do drug value assessments?

The single biggest monetary difference that can be made to the successor to the UK’s 2019 Voluntary Scheme

What’s affordable anyway? The future of NHS drug spending

https://pharmaphorum.com/views-and-analysis/vpas-future-nhs-drug-spending/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Time for a NICE change

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, Leela Barham, market access, NICE 0 Comment

The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and

Time for a NICE change

https://pharmaphorum.com/views-analysis-market-access/time-for-a-nice-change/

Market Access/ Views & Analysis/ Views and analysis

Rises in non-submissions to NICE: do they matter?

Leela Barham Leela Barham, NICE, UK 0 Comment

Leela Barham asks why companies may choose to not submit their drugs to NICE and keep them off

Rises in non-submissions to NICE: do they matter?

https://pharmaphorum.com/views-analysis-market-access/rises-in-non-submissions-to-nice-do-they-matter/

Market Access/ Views & Analysis/ Views and analysis

Getting the most out of technical engagement with NICE

Leela Barham Leela Barham, NICE 0 Comment

In 2017 the UK’s National Institute for Health and Care Excellence (NICE) consulted on changes to help the

Getting the most out of technical engagement with NICE

https://pharmaphorum.com/views-analysis-market-access/getting-the-most-out-of-technical-engagement-with-nice/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Market access in the time of COVID-19

mike.hammerton@pharmaphorum.com coronavirus, COVID-19, Leela Barham, market access 0 Comment

COVID-19 has left no part of life untouched, including health technology assessment (HTA) and other payer agency activities,

Market access in the time of COVID-19

https://pharmaphorum.com/views-analysis-market-access/market-access-in-the-time-of-covid-19/

Digital/ Views & Analysis/ Views and analysis

COVID-19 puts NHS’ app library to the test

Leela Barham apps, coronavirus, COVID-19, digital health, health apps, Leela Barham, NHS 0 Comment

Leela Barham looks at how apps with the NHS’ seal of approval are faring in the market and

COVID-19 puts NHS’ app library to the test

https://pharmaphorum.com/views-and-analysis/covid-19-puts-nhs-app-library-to-the-test/

Market Access/ Views & Analysis/ Views and analysis

Harmonised health technology assessment in Europe? There’s a long way to go

Leela Barham drug market access, Health Technology Assessment, HTA, Leela Barham, market access 0 Comment

Europe is heading towards harmonisation in health technology assessment – but great differences remain in practices and culture

Harmonised health technology assessment in Europe? There’s a long way to go

https://pharmaphorum.com/views-analysis-market-access/harmonised-health-technology-assessment-in-europe-theres-a-long-way-to-go/

Healthcare/ Pharma Market Access/ UK & Europe/ Views and analysis

Has the UK been best place in the world to invest in life sciences?

Leela Barham Leela Barham, PPRS, UK pharma 0 Comment

How has the UK compared to its European peers in terms of supporting growth and innovation in the

Has the UK been best place in the world to invest in life sciences?

https://pharmaphorum.com/views-and-analysis/uk-best-place-world-invest-life-sciences/

Articles/ Healthcare/ Pharma Market Access/ UK & Europe/ Views and analysis

Could the PPRS support a changing growth and innovation agenda?

Leela Barham Innovation, Leela Barham, life sciences industrial strategy, Life Sciences Sector Deal, Pharmaceutical Price Regulation Scheme, PPRS 0 Comment

Has the PPRS delivered on the aim to support the government’s growth and innovation agenda?

Could the PPRS support a changing growth and innovation agenda?

https://pharmaphorum.com/views-and-analysis/pprs-support-changing-growth-innovation-agenda/

Trending

Leela Barham

Login